ANI Pharmaceuticals Q3 2026: Cortrophin Gel Powers Growth, Guidance Gets a Lift, and Egetis on the Radar

Quarterly results at a glance

• Quarterly net revenues: $290.8 million, up 27.6% year over year.
• Cortrophin Gel net revenues: $138.7 million, up 36.1% YoY.
• GAAP net income: $35.1 million for the quarter; GAAP diluted EPS: $1.51.
• Adjusted non-GAAP EBITDA: $83.3 million; adjusted non-GAAP diluted EPS: $2.70.

Guidance, capital allocation, and a pivot toward Rare Disease

ANI narrowed its 2026 total company revenue guidance to a range of $1,085 million to $1,125 million. Cortrophin Gel revenue is now forecast at $480 million to $500 million for the year. In tandem, the company increased its targets for profitability metrics: adjusted non-GAAP EBITDA to $290 million–$300 million, and adjusted non-GAAP diluted EPS to about $9.37–$9.71 for 2026.

Management also highlighted ongoing capital allocation: a year-to-date repurchase of about $20 million in common stock, signaling confidence in the business’s cash generation and the stock’s value. The quarterly print comes as ANI advances a strategic move to broaden its Rare Disease footprint through an announced offer to acquire Egetis Therapeutics, expanding the company’s scale in an area with significant long-term growth potential.

As is typical in these disclosures, analysts will juxtapose EPS and EPS consensus against the updated revenue forecast, with particular attention to whether the Cortrophin Gel growth trajectory can sustain the trajectory implied by the revised guidance. The narrative here is not a fireworks show; it’s a series of incremental, credible steps toward a more diversified portfolio.

Strategic moves and the Rare Disease tilt

In the Rare Disease section, ANI highlights Cortrophin Gel’s role as a growth vehicle, underpinned by expansion in gout and continued progress across Nephrology, Neurology, Rheumatology, Ophthalmology, and Pulmonology. The company frames its Rare Disease push as a core strategic lever, with the Egetis Therapeutics deal as a potential accelerant to bring an FDA-approved rare disease therapy into its fold. The MCT8 deficiency indication referenced in the Egetis discussion underscores a long‑cycle, high‑need opportunity that could meaningfully shift ANI’s product mix over time.

From a finance perspective, the Egetis move introduces a classic capital-allocation fork: grow within, or grow through M&A; either path implies higher cash burn in the near term if the deal closes, but a potential accretion in the long run if the strategic rationale holds and synergies materialize. The company’s cash balance and share repurchase cadence suggest it’s balancing near-term certainty with longer-term bets on Rare Disease adjacency.

What this could mean for ANI and industry peers

The Q3 print reinforces a few persistent themes in Pharmaceuticals: a stable core revenue base, a meaningful growth driver in a branded specialty asset, and a willingness to deploy capital to reposition the portfolio. For sector peers, the combination of steady top-line growth and a clear pivot toward Rare Disease could sharpen M&A chatter in this space, especially among mid-cap players looking for scale and higher-margin opportunities outside legacy generics.

Investors may watch closely how the Egetis proposal evolves—announced deals can stall or accelerate based on regulatory scrutiny, financing terms, and the strategic fit. A successful integration could yield earnings leverage over time, but near-term impact will hinge on financing structure, contingency milestones, and integration costs. In the meantime, the Cortrophin Gel momentum provides a nice tailwind to ANI’s top line that peers in the generic/differentiated product space would envy but must defend with sustained execution.

Bottom line and takeaways

ANI’s Q3 2026 results reinforce a narrative of steadier-than-expected growth, anchored by Cortrophin Gel and supported by a capital-allocation stance that includes buybacks and strategic M&A ambition. The updated revenue forecast and higher EBITDA and EPS targets suggest management is confident in the trajectory into 2027, even as it navigates the headwinds and uncertainties common to specialty pharma—pricing, reimbursement, and regulatory risk among them.

For investors, the key questions post-release are straightforward: will the Egetis deal close and, if so, at what price and with what financing mix? How durable is Cortrophin Gel’s 2026 growth into 2027, and how will that translate into earnings power after the mix shift toward Rare Disease? And, as always, how do the quarterly prints compare with the EPS consensus over the next few quarters as analysts recalibrate expectations?

Executive perspective

“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company,” said Nikhil Lalwani, President and CEO. The tone is pragmatic—growth remains anchored in Cortrophin Gel, with a clear roadmap toward a larger Rare Disease portfolio and a disciplined capital plan.